Pan Cancer T Appoints Dr. Rachel Abbott as Chief Scientific Officer
January 17, 2023 04:00 ET
|
AKAMPION
- Strengthening of T cell research expertise to develop next-generation T cell therapies for patients with limited or no treatment options ROTTERDAM, January 17, 2023 - Pan Cancer T B.V., a...
1ST Biotherapeutics, Inc., Announces FDA Clearance of IND Application for Phase 1/2 Study of FB849 to Treat Patients with Advanced Solid Tumors
December 13, 2022 04:00 ET
|
AKAMPION
- Initiation of Phase 1/2 Clinical Trial Expected in Q1 2023 YONGIN, South Korea, December 13, 2022 -- 1ST Biotherapeutics, Inc., a clinical-stage biotechnology company focused on the development...
Rewind Therapeutics Appoints Dr. Stephen Burbidge to its Management Team
November 29, 2022 04:00 ET
|
AKAMPION
- Former GlaxoSmithKline and Proximagen executive adds to Rewind´s drug discovery and development expertise Leuven, Belgium, November 29, 2022 --- Rewind Therapeutics, a company developing...
HpVac Appoints Joana Vitte, MD, PhD, as Chief Scientific Officer
November 23, 2022 04:00 ET
|
AKAMPION
- Significant expansion of allergy research expertise Geneva, Switzerland, November 23, 2022 – HpVac SA, a company developing novel preventive and therapeutic first-line therapies against...
Dopavision Appoints Dr. Dirk Sauer as Chair of the Company's Advisory Board
November 16, 2022 04:00 ET
|
AKAMPION
- Former Head of Novartis' Ophthalmology Development Unit to provide significant product development expertise and industry network Berlin, Germany, November 16, 2022 --- Dopavision, a...
ImmunOs Therapeutics´ Lead Program Shows Strong Anti-Tumor Activity In Vivo and In Vitro
November 15, 2022 04:00 ET
|
AKAMPION
- Promising data presented at Protein and Antibody Engineering Summit (PEGS) - Multi-functional agent targeting three immune checkpoint receptors - Potential as mono- and combination therapy for...
Rewind Therapeutics Appoints Irene Knuesel, PhD, as Chief Scientific Officer
October 19, 2022 04:00 ET
|
AKAMPION
- Former Roche Head of Neuroimmunology strengthens Rewind´s neuroimmunology and neurodegeneration expertise Leuven, Belgium, October 19, 2022 --- Rewind Therapeutics, a company developing...
HpVac Announces New Animal Data of its Lead Compound Demonstrating Protection Against Allergic Asthma
October 18, 2022 04:00 ET
|
AKAMPION
- Major milestone for accelerating the development of HpVac-13 in allergic diseases Geneva, Switzerland, October 18, 2022 – HpVac SA, a company developing novel preventive and therapeutic...
1ST Biotherapeutics, Inc., Announces Positive Phase I Data of c-Abl Inhibitor in Neurodegeneration
October 18, 2022 03:00 ET
|
AKAMPION
- Compound demonstrates excellent safety and tolerability in single ascending dose trial - Efficient penetration of blood-brain barrier YONGIN, South Korea, October 18, 2022 -- 1ST...
ImmunOs Therapeutics Appoints Dr. Hilmar Ebersbach as Vice President Antibody Development and Protein Engineering
October 17, 2022 04:00 ET
|
AKAMPION
- Former Novartis director brings significant expertise in drug discovery and development Schlieren (Zurich Area), Switzerland, and Gaithersburg, MD, USA – October 17, 2022 – ImmunOs Therapeutics...